Medications for the treatment of opioid use disorder (MOUD) such as buprenorphine are the most effective treatment available for OUD; yet, beyond drug testing results and retention in care, systematically measured clinical outcomes have proven elusive. There is growing interest in integrating systematic monitoring of patient-reported outcomes and measurement-based care as strategies to improve patients’ success in treatment.
Methods:
We analyzed changes in recovery capital assessed via the Brief Assessment of Recovery Capital (BARC-10) from baseline to 30-120 days post-intake among patients initiating buprenorphine treatment from May to October 2023 at Ophelia, a telehealth MOUD provider, who were retained for ≥90 days. Differences in baseline characteristics were assessed between patients with and without high “remission-predictive” baseline scores (≥47) using chi-squared and t-tests. Changes in scores from baseline to follow-up were assessed using paired t-tests.
Results:
In all, 791 patients initiated treatment during the study period, 742 (93.8%) of whom had a baseline BARC-10 score, 542 (73.0%) of whom were retained in treatment for ≥90 days, and 477 of whom (88.0%) had a follow-up BARC-10 score and represent the analysis sample. Older patients, those not requiring buprenorphine induction, and those not using heroin or fentanyl at intake were more likely to have remission-predictive baseline BARC-10 scores (P < .05). Patients with remission-predictive baseline scores (n = 257) had a mean increase of 1.4 (SD = 5.9) from 52.7 (SD = 4.1) (P < .001), and 234 (91%) sustained remission-predictive scores throughout the assessment period. Patients without remission-predictive baseline scores (n = 220) had a mean increase of 9.2 (SD = 8.2) from 38.4 (SD = 6.6) (P < .001), and 129 (59.0%) achieved a remission-predictive score at follow-up.
Conclusions:
Most patients had increased or sustained already high levels of recovery capital, an established predictor of sustained remission. Further research is required to better understand variability across patients and how it may relate to long-term outcomes.
National Academies of Sciesnces, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. The National Academies Press; 2019.
4.
BaoYWilliamsARSchackmanBR.COVID-19 could change the way we respond to the opioid crisis-for the better. Psychiatr Serv. 2020;71(12):1214-1215. doi:10.1176/appi.ps.202000226
5.
LinLAZhangLKimHMFrostMC.Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2022;179(10):740-747. doi:10.1176/appi.ajp.21111141
6.
FrostMCZhangLKimHMLinLA.Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Netw Open. 2022;5(10):e2236298. doi:10.1001/jamanetworkopen.2022.36298
7.
HammerslagLRMackAChandlerRK, et al. Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for medicaid enrollees. JAMA Netw Open. 2023;6(10):e2336914. doi:10.1001/jamanetworkopen.2023.36914
8.
JonesCMShoffCHodgesK, et al. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiatry. 2022;79(10):981-992. doi:10.1001/jamapsychiatry.2022.2284
9.
WeintraubEGreenblattADChangJHimelhochSWelshC.Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018;27(8):612-617. doi:10.1111/ajad.12805
10.
WilliamsARAronowitzSVRoweCGallagherRBeharEBisagaA.Telehealth for opioid use disorder: retention as a function of demographics and rurality. Am J Drug Alcohol Abuse. 2023;49(2):260-265. doi:10.1080/00952990.2023.2180382
11.
WilliamsARAronowitzSGallagherRBeharEGrayZBisagaA.A virtual-first telehealth treatment model for opioid use disorder. J Gen Intern Med. 2023;38(3):814-816. doi:10.1007/s11606-022-07955-x
12.
BiondiBEZhengXFrankCAPetrakisISpringerSA.A Literature review examining primary outcomes of medication treatment studies for opioid use disorder: what outcome should be used to measure opioid treatment success?Am J Addict. 2020;29(4):249-267. doi:10.1111/ajad.13051
13.
MartinSAChiodoLMWilsonA.Article commentary: retention in care as a quality measure for opioid use disorder. Subst Abus. 2019;40(4):453-458. doi:10.1080/08897077.2019.1635969
14.
SamplesHWilliamsARCrystalSOlfsonM.Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid. Health Aff (Millwood). 2020;39(5):747-755. doi:10.1377/hlthaff.2019.01085
15.
HookerSAShermanMDLonergan-CullumMNisslyTLevyR.What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. J Subst Abuse Treat. 2022;141:108804. doi:10.1016/j.jsat.2022.108804
16.
ReedMKSmithKRCioccoF, et al. Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program. Subst Abuse Treat Prev Policy. 2023;18(1):4. doi:10.1186/s13011-022-00510-1
17.
KilukBDKleykampBAComerSD, et al. Clinical trial design challenges and opportunities for emerging treatments for opioid use disorder: a review. JAMA Psychiatry. 2023;80(1):84-92. doi:10.1001/jamapsychiatry.2022.4020
18.
LewisCCBoydMPuspitasariA, et al. Implementing measurement-based care in behavioral health: a review. JAMA Psychiatry. 2019;76(3):324. doi:10.1001/jamapsychiatry.2018.3329
19.
ShimokawaKLambertMJSmartDW.Enhancing treatment outcome of patients at risk of treatment failure: meta-analytic and mega-analytic review of a psychotherapy quality assurance system. J Consult Clin Psychol. 2010;78(3):298-311. doi:10.1037/a0019247
20.
GondekDEdbrooke-ChildsJFinkEDeightonJWolpertM.Feedback from outcome measures and treatment effectiveness, treatment efficiency, and collaborative practice: a systematic review. Adm Policy Ment Health. 2016;43(3):325-343. doi:10.1007/s10488-015-0710-5
21.
KrägelohCUCzubaKJBillingtonDRKerstenPSiegertRJ.Using feedback from patient-reported outcome measures in mental health services: a scoping study and typology. Psychiatr Serv. 2015;66(3):224-241. doi:10.1176/appi.ps.201400141
22.
TamHERonanK.The application of a feedback-informed approach in psychological service with youth: systematic review and meta-analysis. Clin Psychol Rev. 2017;55:41-55. doi:10.1016/j.cpr.2017.04.005
23.
LambertMJWhippleJLHawkinsEJVermeerschDANielsenSLSmartDW.Is it time for clinicians to routinely track patient outcome? A meta-analysis. Clin Psychol Sci Pract. 2003;10(3):288-301. doi:10.1093/clipsy.bpg025
24.
WaldropJMcGuinnessTM.Measurement-based care in psychiatry. J Psychosoc Nurs Ment Health Serv. 2017;55(11):30-35. doi:10.3928/02793695-20170818-01
25.
FortneyJCUnützerJWrennG, et al. A Tipping point for measurement-based care. Psychiatr Serv. 2017;68(2):179-188. doi:10.1176/appi.ps.201500439
26.
WilliamsKSansoniJMorrisDGrootemaatPThompsonC.Patient-Reported Outcome Measures: Literature Review. Australian Commission on Safety and Quality in Healthcare; 2016.
27.
MarsdenJTaiBAliRHuLRushAJVolkowN.Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?Addiction. 2019;114(8):1346-1353. doi:10.1111/add.14546
28.
RushAJGore-LangtonREBartG, et al. Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus. Addict Sci Clin Pract. 2024;19(1):14. doi:10.1186/s13722-024-00446-w
29.
KarnikNSMarsdenJMcCluskeyC, et al. The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study. Addiction. 2022;117(9):2438-2447. doi:10.1111/add.15875
30.
SimpsonDD.A conceptual framework for drug treatment process and outcomes. J Subst Abuse Treat. 2004;27(2):99-121. doi:10.1016/j.jsat.2004.06.001
31.
VeilleuxJCColvinPJAndersonJYorkCHeinzAJ.A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155-166. doi:10.1016/j.cpr.2009.10.006
32.
ScottKLewisCC.Using measurement-based care to enhance any treatment. Cogn Behav Pract. 2015;22(1):49-59. doi:10.1016/j.cbpra.2014.01.010
33.
CacciolaJSAltermanAIDephilippisD, et al. Development and initial evaluation of the brief addiction monitor (BAM). J Subst Abuse Treat. 2013;44(3):256-263. doi:10.1016/j.jsat.2012.07.013
34.
MarsdenJFarrellMBradburyC, et al. Development of the treatment outcomes profile. Addiction. 2008;103(9):1450-1460. doi:10.1111/j.1360-0443.2008.02284.x
35.
BradleyKACaldeiroRMHallgrenKAKivlahanDR.Making measurement-based care for addictions a reality in primary care. Addiction. 2019;114(8):1355-1356. doi:10.1111/add.14605
36.
BeidasRSStewartREWalshL, et al. Free, brief, and validated: Standardized instruments for low-resource mental health settings. Cogn Behav Pract. 2015;22(1):5-19. doi:10.1016/j.cbpra.2014.02.002
37.
BrayJWAdenBEggmanAA, et al. Quality of life as an outcome of opioid use disorder treatment: a systematic review. J Subst Abuse Treat. 2017;76:88-93. doi:10.1016/j.jsat.2017.01.019
38.
BurkeBClearBRollstonRLMillerENWeinerSG.An assessment of the one-month effectiveness of telehealth treatment for opioid use disorder using the brief addiction monitor. Subst Use Addctn J. 2024;45(1):16-23. doi:10.1177/29767342231212790
39.
BormannNLWeberANArndtSLynchA.Improvements in recovery capital are associated with decreased alcohol use in a primary opioid use disorder treatment-seeking cohort. Am J Addict. 2023;32(6):547-553. doi:10.1111/ajad.13431
40.
BormannNLWeberANMiskleBArndtSLynchAC.Recovery capital gains may precede craving reduction in opioid use disorder. Subst Abuse Rehabil. 2023;14:113-118. doi:10.2147/SAR.S433350
41.
LynchACWeberANHeddenSSabbaghSArndtSAcionL.Three-month outcomes from a patient-centered program to treat opioid use disorder in Iowa, USA. Subst Abuse Treat Prev Policy. 2021;16(1):8. doi:10.1186/s13011-021-00342-5
42.
GranfieldRCloudW.Coming Clean: Overcoming Addiction without Treatment. New York University Press; 1999.
43.
KellyJFHoeppnerB.A biaxial formulation of the recovery construct. Addict Res Theory. 2015;23(1):5-9. doi:10.3109/16066359.2014.930132
44.
VilsaintCLKellyJFBergmanBGGroshkovaTBestDWhiteW.Development and validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder. Drug Alcohol Depend. 2017;177:71-76. doi:10.1016/j.drugalcdep.2017.03.022
45.
Parlier-AhmadABTerplanMSvikisDSEllisLMartinCE.Recovery capital among people receiving treatment for opioid use disorder with buprenorphine. Harm Reduct J. 2021;18(1):103. doi:10.1186/s12954-021-00553-w
46.
ShadowenCJalloNParlier-AhmadAB, et al. What recovery means to postpartum women in treatment for opioid use disorder. Womens Health Rep. 2022;3(1):93-103. doi:10.1089/whr.2021.0064
YedinakJLGoedelWCPaullK, et al. Defining a recovery-oriented cascade of care for opioid use disorder: a community-driven, statewide cross-sectional assessment. Alegria M, ed. PLoS Med. 2019;16(11):e1002963. doi:10.1371/journal.pmed.1002963
49.
MarkTLMcGaffeyFKoppelmanJYastishockV.State Measures for Improving Opioid Use Disorder Treatment: Implementation Toolkit. RTI International; 2022.
50.
National Academies of Sciences, Engineering, and Medicine. Measuring Success in Substance Use Grant Programs: Outcomes and MEtrics for Improvement. The National Academies Press; 2020.
51.
O’BrienJWachinoV.Recommendations for Medicaid Performance Measures for Opioid Use Disorder Services in Jails and Prisons. Viaduct Consulting, LLC; 2023.
52.
WilliamsARRoweCGallagherRAronowitzSVDiamond-ReivichJBisagaA.Urine drug screening in a telehealth setting for the treatment of opioid use disorder. JAMA Health Forum. 2023;4(7):e232247. doi:10.1001/jamahealthforum.2023.2247
53.
WilliamsARRoweCMinarikLGrayZMurphySMPincusHA.Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment. Health Aff Sch. 2024;2:qxae009. doi:10.1093/haschl/qxae009
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
